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Abstract 
Testicular Sertoli cell tumors (SCT) are rare and most fall into the category of SCT-not otherwise 
specified (SCT-NOS).  Only a few additional types of SCT are recognized.  Sclerosing SCT (S-SCT), originally 
described in 1991, comprises a small fraction of SCTs and was considered a specific entity until the 2016 
revision of the World Health Organization classification of non-germ cell tumors, where it was classified 
as a morphologic variant of SCT-NOS.  In a recent study, differences in expression of PAX2/PAX8, inhibin, 
androgen receptor and S100 protein between SCT-NOS and S-SCT were noted in a small number of 
cases. In this interinstitutional study, we compared the expression of these markers and β-catenin in 11 
cases each of SCT-NOS and S-SCT to determine if differences exist that could justify keeping a separate 
classification of these neoplasms. PAX2/PAX8 cocktail was the only marker that was significantly 
overexpressed in S-SCT. Expression of androgen receptors was strong in S-SCT and variable in SCT-NOS, 
but did not reach statistical significance. Expression of β-catenin was common in both, while inhibin was 
infrequent. The available material was insufficient for a conclusive evaluation of S100 protein 
expression. Overall, our results support the inclusion of S-SCT as a morphologic variant of SCT-NOS. 
Expression of PAX2/PAX8 in S-SCT may reflect an overactive epithelial to mesenchymal transition as has 
been shown in experimental models of acute and chronic seminiferous tubular injury and might be 
related to the process generating the stroma in these tumors. 
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Introduction 
Testicular Sertoli cell tumors (SCT) are rare: the incidence of testicular neoplasms in the US is 
~6/100,000/year, and of these SCTs comprise only 1% [1,2]. Although morphologically diverse, most 
SCTs fall into the category of SCT-not otherwise specified (SCT-NOS), most are benign, and only a few 
additional types of SCT have been recognized [3].  Sclerosing SCT (S-SCT), originally described by 
Zukerberg, Young and Scully in 1991 [4], comprises a small fraction of SCTs. The largest series to date 
was compiled by Kao and the senior author (T.M.U.) [5], and was considered a specific entity until the 
2016 revision of the World Health Organization (WHO) classification of non-germ cell tumors, in which it 
was designated a morphologic variant of SCT-NOS because both tumors shared clinical similarities, 
mutations of the β-catenin (CTNNB1) gene, and differed only in the amount of associated non-neoplastic 
stroma [2,6]. However, in a recent comparative immunophenotypic study differences in expression of 
PAX2/PAX8 cocktail, inhibin, androgen receptor and S100 protein between SCT-NOS and S-SCT [7] were 
noted, although the number of examined cases (3 of each) was too small to draw definitive conclusions. 
In this interinstitutional study, we compared the expression of these markers and β-catenin in 22 SCTs, 
including 11 cases each of SCT-NOS and S-SCT, to determine if aside from morphologic differences 
immunophenotypic differences also exist that might justify the separate classification of these 
neoplasms. 
Material and Methods 
SCT-NOS and S-SCT from previous studies were retrieved from the pathology databases from Indiana 
University (Indianapolis, IN, USA) and hospitals affiliated with the University of Minnesota (Minneapolis, 
MN, USA). Given the rarity of these tumors and difficulty in obtaining study cases, the expression of 
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PAX2/PAX8 cocktail, inhibin, androgen receptors, S100 protein and β-catenin was evaluated in already 
performed immunohistochemical stains, and, in cases with available unstained slides or paraffin 
embedded blocks, newly performed stains, prioritizing PAX2/PAX8 cocktail> inhibin> androgen 
receptors>β-catenin> S100. Nodules of immature tubules (Sertoli cell nodules, Pick adenomas/tubular 
congeries), androgen insensitivity syndrome-associated lesions, and malignant SCTs were excluded. 
Immunohistochemical studies performed included inhibin A (Novacastra, catalog # NCL-L-Inhibin A, 
Newcastle upon Tyne, UK; dilution 1:1500), androgen receptor (Bio SB, Santa Barbara, CA, catalog # BSB 
6074; dilution 1:10), PAX2 (Bio SB, Santa Barbara, CA, catalog # BSB 2566, pre-dilute), PAX8 (Cell 
Marque, Rocklin, CA; catalog # 363M-14, dilution:1:200), β-catenin (Cell Marque, Rocklin, CA; catalog # 
224M-14; dilution 1:300) and S100 protein (Novacastra, catalog #CL-L-S100P, Newcastle upon Tyne, UK; 
dilution 1:1600). Immunohistochemistry was performed on a Leica BOND-III automated stainer (Leica 
Biosystems, Melbourne, Australia) using EDTA buffer antigen retrieval protocols. PAX2/PAX8 cocktail, β-
catenin and androgen receptor were considered positive only if nuclear staining was present; inhibin 
and S100 protein was considered positive if cytoplasmic staining was present. The intensity of 
expression was graded as: 0= negative, 1=weak, 2=moderate, 3=strong relative to the internal control 
cells (if present) or external control cells in each preparation, and the area of expression as: 0= negative, 
1= 1-5%, 2= 6-50% and 3= >50%.   Statistical analysis was performed using MedCalc Statistical Software 
version 16.8 (MedCalc Software bvba, Ostend, Belgium; https://www.medcalc.org; 2016). The study was 
performed in compliance with institutional guidelines (Veterans Health Administration handbook 
1200.05). 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Results 
A total of 22 cases, including 11 cases each of S-SCT and SCT-NOS, were retrieved, the majority from the 
consultation files of the senior author (T.M.U.).  Table 1 summarizes the results of the 
immunohistochemical studies performed. Expression of PAX2/PAX8 cocktail was demonstrated in most 
S-SCT (8/10; 80%), while most SCT-NOS were negative (1/11; 9%). Expression of inhibin A and β-catenin 
was similar in both groups: most lesions were negative for inhibin A (S-SCT 2/9, 22%; SCT-NOS 3/11, 
27%), but positive for β-catenin (S-SCT 8/10, 80%; SCT-NOS 7/11, 64%).  Expression of androgen 
receptor was present in most tumors and overall it was the most consistent marker (S-SCT 8/9, 89%; 
SCT-NOS 10/11, 91%). In all S-SCT androgen receptor expression was strong, while in SCT-NOS it was 
variable: weak in 4/10, moderate in 4/10 and strong in 2/10. Expression of S100 protein was only tested 
in a few cases in each group: 3/11 S-SCT and 4/11 SCT-NOS; weak to moderate partial expression was 
present in all S-SCT, while all SCT-NOS were negative.  A two-tailed t-test was calculated for all markers 
except S100 protein given the scant number of data points (table 1); the only marker that showed 
statistical significance was PAX2/PAX8 cocktail (p=0.0006).  
Discussion 
The original description of S-SCT [4] in 1991 included 10 cases that comprised 5% of testicular sex cord-
stromal cell tumors and 15% of SCT from the consultation and hospital files at the Massachusetts 
General Hospital (Boston, MA). These tumors diverged from SCT-NOS by their distinct morphology 
characterized by anastomosing tubules, nests or cords in a prominent hypocellular, collagenous 
background and scant entrapped Sertoli-cell-only tubules (fig 1).  The clinical characteristics of the 
cohort did not differ from those of patients with SCT-NOS. One of the cases showed cytologic atypia, 
frequent mitoses, angioinvasion, and invaded the rete testis and epididymis; however, after a mean 
follow-up of ~ 6 years none had evidence of recurrence or metastasis after simple orchiectomy. The 
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described histologic features were distinct enough that subsequent studies followed, mostly as case 
reports.   The definition was later narrowed in the WHO and AFIP classifications to require that the 
fibrous stroma should comprise at least 50% of the tumor [3,8] because focal fibrosis or deposition of 
basement membrane like collagen is common in SCT and Sertoli cell nodules, respectively. Segregation 
of this tumor was based both on its distinct morphology and the benign clinical course, in contrast to 
SCT-NOS. In the largest series of S-SCT compiled by Kao et al. in 2014, however, one of 20 cases pursued 
a malignant course and led to the patient’s death [5].  The recognition of a malignant case showed that 
aside from the exaggerated non-neoplastic fibrous stroma there were no distinctive clinical and 
prognostic differences between S-SCT and SCT-NOS; the biologic behavior of individual tumors can be 
predicted more or less accurately by established clinicopathologic criteria for SCTs [3,8].   
Further evidence linking S-SCT and SCT-NOS was presented in 2014 when Perrone et al. found that 
CTNNB1 exon 3 mutations are common in SCT-NOS and S-SCT and correlate with nuclear 
expression/accumulation of β-catenin and cyclin D1 [9]. A subsequent study of a larger number of cases 
by 2 of the authors (C.Z. and T.U.M.) verified the frequent expression of nuclear β-catenin in tumors of 
both morphologic types [6]. The accumulated evidence, therefore, led to the discontinuation of S-SCT as 
a separate entity in the 2016 WHO classification, where it was considered a morphologic variant of SCT-
NOS.  Nonetheless, a comparative immunophenotypic study of SCTs using an extensive panel in 2017 by 
two of the authors (H.M., C.M.) reported differences in the expression of PAX2/PAX8 cocktail, inhibin, 
androgen receptor and S100 protein between S-SCT and SCT-NOS; however, that study included only 3 
cases of each category, making it impossible to perform any meaningful statistical analysis [7] (fig1). We 
have now performed an interinstitutional cooperative study to determine if the previous findings 
represented random phenotypic variations, or consistent immunophenotypic differences between these 
tumors that might justify maintaining S-SCT as a separate entity. Our results showed a highly significant 
statistical difference in the expression of PAX2/PAX8 cocktail, no differences in inhibin and β-catenin 
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expression, and variation in the intensity of expression of androgen receptors that did not reach 
statistical significance. Expression of S100 protein was only documented in a few cases and could not be 
adequately evaluated. Despite the significant difference in expression of PAX2/PAX8 cocktail, overall 
SCT-NOS and S-SCT appear to have more commonalities than differences, supporting the recent 
modification of the WHO classification. In one of our cases the two tumors coexisted in the same testis, 
along with Sertoli cell nodules, similarly to one of the cases reported in the original series [4].  
The capacity of inducing deposition of hypocellular fibrous stroma is inherent to non-neoplastic Sertoli 
cells and occurs frequently in the context of disease processes leading to testicular atrophy. We have 
previously shown consistent immunophenotypic differences between Sertoli cells from atrophic and 
non-atrophic tubules: gain of expression of pankeratin, calretinin, CD56 and nestin [7], suggesting that 
the fibrous obliteration of atrophic tubules represents an active process that involves activation of a 
mesenchymal/stromal physiologic alternative cell program under abnormal conditions. However, gain of 
expression of PAX2/PAX8 was not identified in atrophic tubules. It is apparent that this program is 
overactive in S-SCT, and may be related to the exaggerated fibrosis.   We confirmed aberrant expression 
of PAX2/PAX8 cocktail in most S-SCT, a marker that in the testis has been traditionally associated with 
lesions derived from the rete testis and epididymis [10]. These proteins are involved in the regulation of 
gene expression: in the embryo, they cause repression of pluripotency genes and in the adult, 
participate in regulation of lineage specification. Interestingly, PAX2 and WT1 are required for epithelial 
to mesenchymal transition and are re-expressed in experimental models of tubular epithelial-to 
mesenchymal transition during acute and chronic injury [11]. Expression of this marker thus supports 
the argument that in S-SCT the “atrophic/injury”-program is overactive.  We confirmed the consistent 
expression of β-catenin and androgen receptor, and the low frequency of expression of inhibin in both 
tumors; these results provide additional information regarding their use as ancillary tests in the work-up 
of testicular neoplasms. 
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Conclusions 
From the immunophenotypic differences previously noted in a limited sample of S-SCT and SCT-NOS 
only the expression of PAX2/PAX8 cocktail was statistically significant. Expression of β-catenin and 
androgen receptor is common in both tumors; expression of androgen receptors is strong in S-SCT and 
variable in SCT-NOS, however differences are not statistically significant. Expression of inhibin is 
uncommon in both tumors, and cannot be used as a reliable marker to support their diagnosis. Overall, 
our results confirm previous observations and support the inclusion of S-SCT as a morphologic variant of 
SCT-NOS. Strong sclerosis of the non-tumoral stroma could be related to activation of similar pathways 
to those leading to fibrous obliteration of seminiferous tubules in the context of atrophy or injury.  
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Figure Legend 
Figure 1. Sclerosing Sertoli cell tumor.  A. Low power showing anastomosing cords in a hypocellular 
fibrous background. The lower right corner shows a cluster of lipidized tumor cells (H&E, 5X objective). 
B. Intermediate power showing alternation of cords and nests of cells with moderate and scant 
cytoplasm and dense fibrosis (H&E, 20X objective). Immunohistochemical studies: C. Androgen receptor 
(nuclear): strong consistent expression (20X objective). D. Beta catenin (nuclear): strong consistent 
expression (20X objective). E. PAX2/PAX8 cocktail (nuclear): variable, moderate to strong expression 
(40X objective). F. S100 protein (cytoplasmic): variable, moderate to strong expression (20X objective). 
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Table. Immunohistochemical stains  
Marker S-SCT SS±SD (n) SCT-NOS SS±SD (n) P value 
Pax2/Pax8 3.3±1.1 (10) 0.5±0.9 (11) 0.0006* 
Inhibin A 1.2±1.2 (9) 1.6±1.4 (11) 0.5071 
Androgen Receptor 5.3±1 (9) 4.4±1.1 (11) 0.0743 
β-Catenin 4.6±1.3 (10) 3.8±1.5 (11) 0.800 
S100 4.3±0.8 (3) 0 (4) N.C. 
S-SCT=sclerosing Sertoli cell tumor. SCT-NOS= Sertoli Cell tumor not otherwise specified. SS= Staining 
Score: (mean intensity score + mean area score). Intensity score= 0: negative, 1: weak, 2: moderate, 3: 
strong.  Area score= 0: none, 1: 1-5%, 2: 6-50%, 3: >51%. SD= standard deviation. n=number of cases 
tested. P value=calculated probability two-tailed T-Test. *Significant p-value < 0.05. N.C.=not calculated 
due to insufficient data points. 
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Figure 1 
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Highlights 
 Testicular Sertoli cell tumors (SCT) are rare and most are benign  
 Most SCT are classified as not otherwise specified (SCT-NOS) 
 Sclerosing SCT (S-SCT) is now considered a variant of SCT-NOS 
 Immunophenotypic differences between SCT-NOS and SCT-NOS were reported 
 S-SCT and SCT-NOS differ only in the amount of fibrosis and expression of PAX2/PAX8  
